Introduction: Heart failure (HF) is a frequent cause of death in Africa. This study aims to determine the mortality rate of HF and to highlights its associated factors. Methods: We conducted a retrospective cross-sectional study in the Department of Cardiology at the Libreville University Hospital. It focused on the analysis of the records of patients hospitalized for left or global HF. Data were collected from January 2014 to December 2016. Results: Fatality rate accounted for 10.3%. The average age of dead patients (n=64) was 57,4 +/- 17 years. Mean delay in treatment was 15 +/- 18 days and decompensated heart failure was caused by a treatment gap in 51.4% of died patients. The association between high blood pressure and diabetes significantly increased the risk of death (OR= 2.2 (1,2-6,6)). The factors associated with mortality rate were essentially: arterial hypotension (OR=6.8 (3,2-14,1)), severe renal impairment (OR=3.5 (1,7-7,2)), cardio-thoracic index higher than 0.7 (OR= 54.4(15,3-193,1)), severe alteration in left ventricular ejection fraction (OR= 3.0(1,5-5,9)) and high NT-proBNP levels (OR=3.5(1,2-10,5)). Mortality increased significantly with the number of co-morbidities. Deaths were due to extracardiac complications in 28.4% of cases. Conclusion: Heart failure mortality is related to the severity and the precocity of the lesions. Delayed treatment and co-morbidities aggravate mortality. The identification of risk factors and a therapeutic education may reduce mortality in relatively young subjects.

The objective of this study was to analyze the effect of hydroxychloroquine or chloroquine associated with azithromycin on the QTc interval in Gabonese patients treated for COVID-19. Methods: This was an observational study conducted from April to June 2020, at the Libreville University Hospital Center in Gabon. Patients admitted for COVID-19 and treated with hydroxychloroquine or chloroquine, each combined with azithromycin were included. The QTc interval was measured upon admission and 48 h after starting treatment. The primary endpoint was QTc prolongation exceeding 60 ms and/or a QTc value exceeding 500 ms at 48 h. Results: Data from 224 patients, 102 (45.5%) who received hydroxychloroquine and 122 treated with chloroquine, were analyzed. The median baseline QTc was 396 (369–419) ms. After 48 h of treatment, 50 (22.3%) patients had a significant prolongation of QTc. This tended to be more frequent in patients treated with chloroquine (n = 33; 27.0%) than in those treated with hydroxychloroquine (n = 17; 16.7%) (p = 0.06). QTc prolongation exceeding 60 ms was found in 48 (21.3%) patients, while 11 patients had a (4.9%) QTc exceeding 60 ms at admission and exceeding 500 ms after 48 h. Conclusion: Early QTc prolongation is frequent in COVID-19 patients treated with hydroxychloroquine or chloroquine in association with azithromycin.

La maladie de Takayasu est une vascularite affectant de façon préférentielle l'aorte et ses principales branches. Mycobacterium tuberculosis peut notamment être un facteur déclenchant du développement de la maladie de Takayasu par une réaction d'hypersensibilité. Le Maghreb et l'Afrique du Sud cumulent le plus grand nombre d'observations africaines, alors qu'entre les deux, en Afrique subsaharienne, les données parcellaires de la maladie font penser que la prévalence de la maladie est probablement sous-estimée/sous-diagnostiquée. Nous en rapportons 5 observations gabonaises.